1.An unusual case of metachronous NK/T cell lymphoma and interdigitating dendritic cell sarcoma.
So Yeon HWANG ; In Sook WOO ; Yosep CHONG ; Chang Suk KANG ; Chi Wha HAN ; Yun Hwa JUNG
Blood Research 2017;52(3):224-227
No abstract available.
Dendritic Cell Sarcoma, Interdigitating*
;
Dendritic Cells*
;
Lymphoma*
2.Mediastinal Actinomycosis Mimicking Mediastinal Lymph Node Metastasis in a Patient with Locally Advanced Pancreatic Cancer.
Jung Won HEO ; Hanna JOUNG ; In Sook WOO ; Chi Wha HAN ; Yun Hwa JUNG
Korean Journal of Medicine 2017;92(3):303-307
Actinomycosis is a rare chronic suppurative infectious disease caused by Actinomyces spp. Actinomyces are anaerobic Gram-positive bacteria that colonize the mouth, digestive tract, and genital tract. Thoracic actinomycosis is caused by the aspiration of oropharyngeal materials or the spread of cervicofacial infections. Therefore, poor oral hygiene, smoking, and immunodeficiency are risk factors. Actinomycoses are frequently misdiagnosed as anatomical malignancies and thus assessments of the diseases underlying malignancies are often complicated by the presence of actinomycoses. Here, we report a case of mediastinal actinomycosis presenting with clinical and radiological features of metastatic pancreatic cancer. Clinicians should consider the presence of actinomycosis when cancer patients fail to respond to anti-cancer treatments.
Actinomyces
;
Actinomycosis*
;
Colon
;
Communicable Diseases
;
Gastrointestinal Tract
;
Gram-Positive Bacteria
;
Humans
;
Lymph Nodes*
;
Mouth
;
Neoplasm Metastasis*
;
Oral Hygiene
;
Pancreatic Neoplasms*
;
Risk Factors
;
Smoke
;
Smoking
3.Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients.
Yun Hwa JUNG ; Won Jik LEE ; Jae Ho BYEON ; In Kyu LEE ; Chi Wha HAN ; In Sook WOO
The Korean Journal of Internal Medicine 2017;32(5):926-929
No abstract available.
Administration, Metronomic
;
Aged*
;
Capecitabine*
;
Colorectal Neoplasms*
;
Drug Therapy*
;
Humans
4.Hypertriglyceridemia Associated with Use of Sunitinib to Treat a Metastatic Pancreatic Neuroendocrine Tumor.
Sanghoon YOO ; Insook WOO ; Yun Hwa JUNG ; Gyohui KIM ; Youngyun CHO ; Chi Wha HAN
Korean Journal of Medicine 2015;88(1):101-105
Sunitinib is a multi-target tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. The most common adverse reactions are known to be nausea, fatigue, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity (hand-foot syndrome), hypothyroidism, and reduction in the cardiac output of the left ventricle. Herein, we report the case of a 57 year-old female who visited our hospital complaining of epigastric pain. She had been taking sunitinib at 25 mg/day to treat a metastatic pancreatic neuroendocrine tumor. Upon computed tomography performed on admission, we observed that fluid had collected around the pancreas. Laboratory analysis revealed hypertriglyceridemia (triglycerides 993 mg/dL). Tyrosine kinase inhibitors are known to have limited effects on lipid metabolism. In this case, we suggest that hyperglycemia seems to have had a limited effect on lipid levels. We are rather of the view that hyperglycemia, a history of distal pancreatectomy, and hypothyrodisim, indirectly caused the observed hypertriglyceridemia.
Carcinoma, Renal Cell
;
Cardiac Output
;
Diarrhea
;
Esophagitis
;
Fatigue
;
Female
;
Gastrointestinal Stromal Tumors
;
Heart Ventricles
;
Humans
;
Hyperglycemia
;
Hypertension
;
Hypertriglyceridemia*
;
Hypothyroidism
;
Lipid Metabolism
;
Nausea
;
Neuroendocrine Tumors*
;
Pancreas
;
Pancreatectomy
;
Protein-Tyrosine Kinases
;
Skin
;
Stomatitis
5.Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Yun Hwa JUNG ; In Sook WOO ; Chi Wha HAN
The Korean Journal of Internal Medicine 2015;30(5):684-693
BACKGROUND/AIMS: Among diffuse large B cell lymphoma (DLBCL) patients, determining the appropriate dose and chemotherapy schedule to balance toxicity and efficacy is harder in elderly than in younger patients. Moreover, there are no currently available clinical factors that consistently identify patients who are unfit to receive chemotherapy. Therefore, the clinical characteristics and outcomes of elderly patients with DLBCL and the causes of treatment-related death were investigated in this study. METHODS: The clinical characteristics and outcomes of 44 elderly (> or = 70 years of age) patients diagnosed with DLBCL between January 2005 and June 2013 were evaluated. Variable clinical data along with the response rate, overall survival (OS), and causes of treatment-related death or treatment interruption were investigated. RESULTS: The median OS was 18.6 months, and 19 patients completed curative treatment. The mean average relative dose intensity of adriamycin in patients who completed chemotherapy was 0.617, and of these patients, 16 achieved complete remission. Chemotherapy incompletion, infectious complications, ex tranoda l involvement, high lactate dehydrogenase, poor performance status, and low albumin level at diagnosis were related to a shorter OS. However, multivariate analysis revealed that only infections and chemotherapy incompletion were significantly related to poor prognosis. The most common cause of treatment-related death was infection, and patients who had experienced infectious complications tended to have lower albumin levels than those of patients without such complications. CONCLUSIONS: In the treatment of elderly lymphoma patients, the dose intensity of adriamycin is not as important as it is in young patients. However, in elderly patients, infections are particularly dangerous, especially in patients with low albumin levels.
Age Factors
;
Aged
;
Aged, 80 and over
;
Antibiotics, Antineoplastic/*administration & dosage/adverse effects
;
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
;
Chi-Square Distribution
;
Communicable Diseases/blood/diagnosis/mortality
;
Disease Progression
;
Doxorubicin/*administration & dosage/adverse effects
;
Female
;
Geriatric Assessment
;
Humans
;
Kaplan-Meier Estimate
;
Lymphoma, Large B-Cell, Diffuse/blood/diagnosis/*drug therapy/mortality
;
Male
;
Multivariate Analysis
;
Proportional Hazards Models
;
Remission Induction
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Serum Albumin/analysis
;
Time Factors
;
Treatment Outcome
6.A Case of Primary Cutaneous Anaplastic Large Cell Lymphoma with Extensive Limb Disease.
Jae Ho BYEON ; In Sook WOO ; Won Jik LEE ; Sung Hee KAM ; Chi Wha HAN ; Yun Hwa JUNG
Korean Journal of Medicine 2015;89(3):353-357
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare subtype of malignant non-Hodgkin lymphoma, in which 40% of the cases show spontaneous regression without aggressive treatment. Surgery and focal radiation therapy are the primary forms of treatment for this disease; however, if pcALCL is accompanied by multifocal skin lesions, chemotherapy is also common. The prognosis for pcALCL is generally excellent, with a 5-year survival rate of 85-100%. However, pcALCL with extensive limb disease typically has a poor prognosis. Here, we present a case of pcALCL with extensive limb disease that resulted in the patient's death, despite the use of aggressive chemotherapy.
Drug Therapy
;
Extremities*
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Lymphoma, Primary Cutaneous Anaplastic Large Cell*
;
Prognosis
;
Skin
;
Survival Rate
7.Two Cases of Primary Esophageal Diffuse Large B Cell Lymphoma: Therapeutic Considerations and a Literature Review.
Ji Hye KIM ; Yun Hwa JUNG ; In Sook WOO ; Chi Wha HAN ; Min Woo SEO ; Sang Hoon YOO ; So Young HA
Korean Journal of Medicine 2015;88(2):224-230
Primary esophageal lymphoma is very rare, and most reported cases are histologically mucosa-associated lymphoid tissue lymphoma. Therefore, the principle treatment strategy for primary esophageal lymphoma focuses on local treatments, such as endoscopic mucosal resection or radiation therapy, but systemic chemotherapy plays the central role in the treatment of diffuse large B cell lymphoma (DLBCL). Generally, standard treatment for DLBCL is six or three cycles of R-CHOP chemotherapy followed by involved field radiation therapy according to stage. However, the optimal treatment strategy for primary esophageal DLBCL, and the role of additional radiation is not settled, due to a paucity of cases. Moreover, the clinical characteristics related to the etiology and natural course are also unknown. Here, we present two cases of primary esophageal DLBCL with a literature review.
Drug Therapy
;
Esophagus
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Large B-Cell, Diffuse
8.Spontaneous bilateral suburothelial hemorrhage in immune thrombocytopenic purpura.
Blood Research 2015;50(1):6-6
No abstract available.
Hemorrhage*
;
Purpura, Thrombocytopenic, Idiopathic*
10.Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer after Treatment with 5-Fluorouracil/Leucovorin and Oxaliplatin: Case Report and Literature Review.
Hyung Duk KIM ; Kyung Sun HA ; In Sook WOO ; Yun Hwa JUNG ; Chi Wha HAN ; Tae Jung KIM
Cancer Research and Treatment 2014;46(2):204-207
Development of tumor lysis syndrome (TLS) may occur after chemotherapy or spontaneously in bulky or rapidly growing tumors. This syndrome is frequent but preventable in patients with hematologic malignancies. TLS following therapy has been reported infrequently in various types of solid tumors. TLS associated with oxaliplatin containing chemotherapy in a solid tumor has never been reported. A 59-year-old man received 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for metastatic colon cancer. Development of TLS occurred three days after administration of chemotherapy. Two days later, his abnormal laboratory findings were recovered with appropriate management. To the best of our knowledge, the current case is the first report on development of acute TLS following oxaliplatin containing chemotherapy in a patient with colon cancer. We also review the literature on tumor lysis syndrome in patients with colorectal cancer.
Colon
;
Colonic Neoplasms*
;
Colorectal Neoplasms
;
Drug Therapy
;
Fluorouracil
;
Hematologic Neoplasms
;
Humans
;
Leucovorin
;
Middle Aged
;
Tumor Lysis Syndrome*

Result Analysis
Print
Save
E-mail